Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Claudio G. Brunstein,1 Jonathan A. Gutman,2 Daniel J. Weisdorf,1 Ann E. Woolfrey,2 Todd E. DeFor,1 Theodore A. Gooley,2 Michael R. Verneris,1 Frederick R. Appelbaum,2 *John E. Wagner,1 and *Colleen Delaney2

1University of Minnesota Medical Center, Minneapolis, MN; and 2Fred Hutchinson Cancer Research Center, Seattle, WA

Effectiveness of double umbilical cord blood (dUCB) grafts relative to conventional marrow and mobilized peripheral blood from related and unrelated donors has yet to be established. We studied 536 patients at the Fred Hutchinson Cancer Research Center and University of Minnesota with malignant disease who underwent transplantation with a human leukocyte antigen (HLA)–matched related donor (MRD, n = 204), HLA allele–matched unrelated donor (MUD, n = 152) or 1-antigen–mismatched unrelated adult donor (MMUD, n = 52) or 4-6/6 HLA matched dUCB (n = 128) graft after myeloablative conditioning. Leukemia-free survival at 5 years was similar for each donor type (dUCB 51% [95% confidence interval (CI), 41%-59%]; MRD 33% [95% CI, 26%-41%]; MUD 48% [40%-56%]; MMUD 38% [95% CI, 25%-51%]). The risk of relapse was lower in recipients of dUCB (15%, 95% CI, 9%-22%) compared with MRD (43%, 95% CI, 35%-52%), MUD (37%, 95% CI, 29%-46%) and MMUD (35%, 95% CI, 21%-48%), yet nonrelapse mortality was higher for dUCB (34%, 95% CI, 25%-42%), MRD (24% [95% CI, 17%-39%), and MUD (14%, 95% CI, 9%-20%). We conclude that leukemia-free survival after dUCB transplantation is comparable with that observed after MRD and MUD transplantation. For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative. (Blood. 2010;116(22):4693-4699)

Introduction

Umbilical cord blood (UCB) has been shown to be a valuable alternative source of hematopoietic stem cells (HSCs) for transplantation in patients who lack a suitable related or unrelated donor.1-9 Cell dose is the single most important determinant of successful UCB transplantation in adult patients.10-13 Transplantation of a single UCB unit containing a (prefreeze) cell dose < 2.5 x 10^7 nucleated cells per kilogram or an infused CD34 cell dose of < 1.7 x 10^5 nucleated cells per kilogram has been associated with poor engraftment, high nonrelapse mortality (NRM), and poor survival.14 The infusion of 2 partially human leukocyte antigen (HLA)–matched UCB units was explored as a strategy to achieve this cell dose threshold and make UCB more widely available.14-17 However, to date, the risks and benefits of double UCB transplantation (dUCBT) relative to those observed after transplantations with related and unrelated adult donors have yet to be determined.

Methods

Study design and patient selection

Consecutive patients age ≥10 years and undergoing first allogeneic hematopoietic cell transplantation (HCT) for hematologic malignancy after a high-dose total body irradiation containing conditioning regimen at the Fred Hutchinson Cancer Research Center (FHCRC) and University of Minnesota (UM) between 2001 and 2008 were eligible for this retrospective analysis. Patients had human leukocyte antigen (HLA)–8/8 allele–matched related donors (MRD) or matched unrelated donors (MUD), 1 allele–mismatched unrelated donors (MMUD), or a dUCB graft. All UCB units were HLA-typed at the antigen-level for HLA-A and HLA-B and allele-level for HLA-DRB1. As previously reported, UCB units were HLA 4-6/6 matched with the patient and each other.14 All patients received myeloablative conditioning with cyclophosphamide 120 mg/kg and total body irradiation 1200 to 1320 cGy with the addition of fludarabine 75 mg/m^2 in recipients of dUCBT, and graft–versus–host disease immunophrophylaxis with a calcineurin inhibitor (cyclosporine or tacrolimus) and either methotrexate (MRD, MUD, and MMUD) or mycophenolate mofetil (MRD and dUCB). Supportive care was similar in the 2 centers and included anti-infective prophylaxis in single hospital rooms with high-efficiency particulate air filtration. Antiviral prophylaxis included acyclovir until day 100. Documented cytomegalovirus (CMV) reactivation or infection was treated with ganciclovir or foscarinet. Broad spectrum antibiotics were administered for neutropenic fever and antifungal coverage was added for persistent fever. All patients received fluconazole or voriconazole for prophylaxis of fungal infections for 100 days and trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jiroveci. Extended spectrum fluoroquinolones were administered for encapsulated bacterial prophylaxis during treatment of graft-versus-host disease (GVHD).

Endpoints and definitions

The primary endpoint of this study was leukemia-free survival (LFS) defined as the time from transplantation to first relapse or death during complete remission. Other endpoints included the cumulative incidences of neutrophil recovery (≥ 500/μL by day +45) and platelet recovery (≥ 50 000/μL at day +100 after transplantation) with complete chimerism, cumulative incidence of acute and chronic GVHD at 3 months and 2 years, respectively, and cumulative incidences of NRM at 2 years and relapse at 5 years. Acute and chronic GVHD were recognized and scored using standardized criteria.18,19 Patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) in first complete remission (CR1) or second complete remission (CR2) and chronic myelogenous leukemia

© 2010 by The American Society of Hematology

BLOOD, 25 NOVEMBER 2010 • VOLUME 116, NUMBER 22

4693
Table 1. Patient and graft characteristics

<table>
<thead>
<tr>
<th>Factors</th>
<th>dUCB</th>
<th>MRD</th>
<th>MUD</th>
<th>MMUD</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>128</td>
<td>204</td>
<td>152</td>
<td>52</td>
<td>NE</td>
</tr>
<tr>
<td>Median age at transplantation, y (range)</td>
<td>25 (10-46)</td>
<td>40 (12-67)</td>
<td>31 (10-57)</td>
<td>31 (10-51)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Male</td>
<td>72 (56%)</td>
<td>120 (59%)</td>
<td>95 (63%)</td>
<td>31 (60%)</td>
<td>&lt;.76</td>
</tr>
<tr>
<td>Recipient CMV+</td>
<td>79 (62%)</td>
<td>119 (58%)</td>
<td>67 (44%)</td>
<td>31 (60%)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;.13</td>
</tr>
<tr>
<td>Acute leukemia CR1</td>
<td>58 (45%)</td>
<td>89 (44%)</td>
<td>44 (29%)</td>
<td>13 (25%)</td>
<td></td>
</tr>
<tr>
<td>Acute leukemia CR2</td>
<td>42 (33%)</td>
<td>42 (21%)</td>
<td>42 (28%)</td>
<td>11 (21%)</td>
<td></td>
</tr>
<tr>
<td>Acute leukemia CR3+</td>
<td>16 (13%)</td>
<td>46 (23%)</td>
<td>31 (20%)</td>
<td>13 (25%)</td>
<td></td>
</tr>
<tr>
<td>CML 1st chronic phase</td>
<td>5 (4%)</td>
<td>3 (2%)</td>
<td>4 (8%)</td>
<td>5 (4%)</td>
<td></td>
</tr>
<tr>
<td>CML accelerated phase</td>
<td>3 (2%)</td>
<td>12 (6%)</td>
<td>17 (11%)</td>
<td>11 (21%)</td>
<td></td>
</tr>
<tr>
<td>Stem cell source</td>
<td>NE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BM</td>
<td>NA</td>
<td>17 (8%)</td>
<td>64 (42%)</td>
<td>18 (35%)</td>
<td></td>
</tr>
<tr>
<td>PBSCs</td>
<td>NA</td>
<td>187 (92%)</td>
<td>88 (58%)</td>
<td>34 (65%)</td>
<td></td>
</tr>
<tr>
<td>dUCB</td>
<td>128 (100%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Nucleated cell dose (10⁸/kg)</td>
<td>0.4 (0.2-3.0)</td>
<td>8.6 (1.6-22.2)</td>
<td>2.0 (1.1-14.2)</td>
<td>1.7 (1.6-1.9)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>HLA-matching*</td>
<td>NE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/8</td>
<td>NA</td>
<td>NA</td>
<td>152</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>7/8</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>6/6</td>
<td>NA</td>
<td>204</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>6/6 + 6/6</td>
<td>5 (4%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>6/6 + 5/6</td>
<td>4 (3%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>6/6 + 4/6</td>
<td>1 (1%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>5/6 + 5/6</td>
<td>41 (32%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>5/6 + 4/6</td>
<td>20 (16%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>4/6 + 4/6</td>
<td>57 (45%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Transplant center</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;.01</td>
</tr>
<tr>
<td>FHCRC</td>
<td>24 (19%)</td>
<td>110 (54%)</td>
<td>138 (91%)</td>
<td>50 (96%)</td>
<td></td>
</tr>
<tr>
<td>UM</td>
<td>104 (81%)</td>
<td>94 (46%)</td>
<td>14 (9%)</td>
<td>2 (4%)</td>
<td></td>
</tr>
<tr>
<td>Median follow-up, y (range)</td>
<td>2.1 (0.4-6.9)</td>
<td>3.0 (0.4-7.5)</td>
<td>4.2 (0.3-8.1)</td>
<td>4.6 (2.9-7.5)</td>
<td>&lt;.01</td>
</tr>
</tbody>
</table>

NE indicates not evaluable; CMV+, cytomegalovirus seropositive; CR1, first complete remission; CR2, second complete remission; CR3+, third completed remission, primary induction failures and active leukemia; and NA, not applicable.

*As defined in “Study design and patient selection,” the degree of HLA-matching varies depending on the donor type.

(CML) in first chronic phase (CP1) were considered standard risk of relapse. All remaining patients were considered high risk. For dUCBT recipients, HLA-matching was defined by the worst matched of the 2 units (eg, if one unit was 5/6 and the other 4/6 matched, it was analyzed as a 4/6 HLA-matched graft).

Statistical considerations

Cumulative incidence was used to estimate the endpoints of hematopoietic recovery, relapse, NRM, and acute and chronic GVHD. For neutrophil and platelet recovery and GVHD, death without the event was the competing event. For NRM, relapse was the competing event; for relapse, transplant-related death was the competing event.20 LFS was estimated by the Kaplan-Meier method.21 Comparisons of time-to-event curves were completed by the logrank test. Cox regression was used to assess factors influencing LFS and neutrophil engraftment.22 The proportional hazards model of Fine and Gray was used to assess independent factors on platelet recovery, acute and chronic GVHD, relapse and NRM.23 All factors were tested for proportional hazards before inclusion in the regression models.24 Factors considered in the multivariable models were donor type (MRD vs MUD vs MMUD vs DUCB), diagnosis (ALL vs AML vs CML vs myelodysplastic syndrome [MDS]), disease risk (standard vs high), age (continuous), weight, sex, sex-mismatch, CMV serostatus (donor and recipient negative vs either positive) and time from diagnosis to transplantation (< 1 year vs 1-2 years vs > 2 years). All P-values were 2-sided. The median follow up of survivors was 3.1 years (range, 0.3-8.1 years).

Analyses were performed using SAS 9.2 (SAS Institute) and R 2.4 statistical software. This retrospective analysis was approved by the Institutional Review Board of both institutions.

Results

Patient and graft characteristics

Patient and graft characteristics for the 536 patients are shown in Table 1. Patients were transplanted at FHCRC (n = 322) and UM (n = 214) for the treatment of AML (n = 211), ALL (n = 236), CML (n = 70), and MDS (n = 19). Allografts were from a MRD (n = 204), MUD (n = 152), MMUD (n = 52), or dUCB (n = 128). Differences between donor groups included, higher median age in MRD recipients, more frequent diagnosis of CML in recipients of MUD or MMUD grafts, lower incidence of CMV seropositivity in recipients of MUD grafts, and greater HLA mismatch and shorter follow-up in recipients of dUCB. Sex distribution and disease risk were similar between groups. Peripheral blood stem cells (PBSCs) were used for nearly all MRD grafts (92%) and most MUD grafts (58%) with marrow used more frequently for MMUD grafts (65%). While proportions of patients with MRD grafts were similar between the 2 institutions, MUD and MMUD grafts were more...
commonly used at FHCRC and dUCB was more commonly used at UM. As expected, dUCB grafts contained fewer nucleated cells. The median infused cell doses of the larger and smaller UCBs unit were $2.1 \times 10^7$/kg (range, 1.1-22.0) and $1.6 \times 10^7$/kg (range, 0.6-15) actual recipient body weight, respectively. Only 29 of the 256 infused UCB units contained an infused cell dose $\geq 3.0$/kg of recipient weight.

Leukemia-free survival

The primary endpoint of this analysis was LFS. As shown in Figure 1A and Table 2, LFS at 5 years was similar for all 4 groups. After adjusting for disease risk and time from diagnosis to transplantation, multivariable analysis did not reveal any difference in the relative risk of LFS by donor type (Table 3). In patients with acute leukemia transplanted with a MUD graft, no difference in the relative risk of LFS was observed between recipients of bone marrow (BM, reference group) and PBSC (RR 1.39 [95% confidence interval (CI), 0.74-2.59], $P = .31$). LFS was similar for patients treated at each transplant center (data not shown). For patients $\leq 45$ years (the maximum age for recipients of a myeloablative regimen and dUCBT by design), LFS at 5 years remained similar (Table 2). Additional analyses revealed similar probabilities of LFS for all donor types when restricted to patients $\geq 18$ years ($n = 450$; dUCB, relative risk [RR] 1.0 [reference group]; MRD RR 0.97, 95% CI, 0.69-1.37, $P = .86$; MUD RR 0.79, 95% CI, 0.53-1.17, $P = .24$; MMUD RR 0.97, 95% CI, 0.67-1.69, $P = .78$), and those with acute leukemia (dUCB, RR 1.0 [reference group]; MRD RR 1.09, 95% CI, 0.78-1.52, $P = .62$; MUD RR 1.01, 95% CI, 0.69-1.48, $P = .96$; MMUD RR 0.97, 95% CI, 0.58-1.62, $P = .89$).

Relapse

The cumulative incidence of relapse at 5 years was comparable in recipients of MRD, MUD, and MMUD grafts but lower in recipients of dUCBT (Figure 1B) with similar outcomes in the subset of patients $\leq 45$ years (Table 2). Because the incidence
of early NRM was highest after dUCBT (see “Nonrelapse mortality”), we analyzed the risk of relapse in survivors who were leukemia free at day +100 after transplantation (dUCB = 92, MRD = 163, MUD = 117, and MMUD = 38). In this subgroup, the risk of relapse remained lowest in recipients of dUCB (Table 2). After adjusting for disease risk, interval from diagnosis to transplantation, age at transplantation and diagnosis, multivariable analysis showed lower relative risk of relapse was associated with dUCBT (Table 3). Similarly, the relative risk of relapse remained lower among dUCBT recipients regardless of risk group (for high risk patients: dUCB, RR 1.0 [reference group]; MRD RR 3.6, 95% CI, 1.1-8.9, P < .01; MUD RR 3.6, 95% CI, 1.7-6.5, P = .02; MMUD RR 2.6, 95% CI, 1.18-5.77, P = .02, and for standard risk disease: dUCB, RR 1.0 [reference group]; MRD RR 4.4, 95% CI, 1.82-10.73, P < .01; MUD RR 3.2, 95% CI, 1.22-8.66, P = .02, MMUD RR 3.3, 95% CI, 0.91-12.19, P = .07). Additional analyses revealed similar outcomes when restricted to patients ≥18 years (dUCB, RR 1.0 [reference group]; MRD RR 3.9, 95% CI, 1.94-6.65, P < .01; MUD RR 2.76, 95% CI, 1.41-5.40, P < .01; MMUD RR 2.28, 95% CI, 1.04-5.01, P = .04); or those with acute leukemia (dUCB, RR 1.0 [reference group]; MRD RR 3.8, 95% CI, 2.22-6.72, P < .01; MUD RR 3.4, 95% CI, 1.90-6.09, P < .01; MMUD RR 2.18, 95% CI, 0.99-4.79, P = .05). Leukemia relapse was the most frequent cause of mortality in recipients of MRD, MUD, and MMUD grafts (Figure 2).

Nonrelapse mortality

The cumulative incidence of NRM at 2 years was highest in recipients of dUCB (Figure 1C and Table 2). After adjusting for age at transplantation and diagnosis, multivariable analysis showed that the risk of NRM was higher after dUCBT (Table 3). Analysis of risk factors for NRM among dUCB recipients demonstrated a higher risk in patients with delayed neutrophil recovery (41% [95% CI, 26%-56%] if neutrophil recovery took ≥26 days (median time to neutrophil recovery for dUCB recipients) compared 16% [95% CI, 7%-25%] if recovery was <26 days). If restricted to dUCB recipients with earlier (< median 26 days) to neutrophil recovery after dUCBT, the incidence of NRM was similar in all groups (dUCB, RR 1.0 [reference group]; MRD RR 0.5 [95% CI, 0.2-1.1] P = .07; MUD RR 0.7 [95% CI, 0.3-1.4], P = .30; MMUD RR 1.5 [95% CI, 0.6-3.6], P = .39), emphasizing that delayed engraftment is the single greatest barrier to successful UCBT and the most important contributor to early NRM. As shown in Figure 2, infection was the most common cause of death among recipients of dUCB.

Hematopoietic recovery and GVHD

While the use of dUCB broadens the application of UCB as a stem cell source, hematopoietic recovery in recipients of dUCB remains delayed relative to other donor sources. As shown in Table 2, the median times to neutrophil and platelet recovery are at least 1 week and 4 weeks longer after dUCBT, respectively (Table 2) with lower cumulative incidences of recovery (Figure 1D-E). In multivariable analysis, neutrophil and platelet recovery were slower in recipients of dUCB compared with other donor sources (Table 3), after adjusting for recipient’s age and diagnosis, respectively.

Despite greater HLA mismatch, the cumulative incidence of grade 2-4 acute GVHD was lowest in recipients of dUCB (Table 2, Figure 1F). In multivariable analysis, after adjusting for CMV serostatus, a higher relative risk of grade 2-4 GVHD was associated with MUD or MMUD transplantation (Table 3). In contrast, the cumulative incidence of grade 3-4 acute GVHD was lowest in recipients of MRD grafts (Table 2). With regards to chronic GVHD, the cumulative incidence was lowest among recipients of dUCB (Table 2) even after adjusting for differences in patient age (Table 3).

Discussion

The present study is the first analysis comparing the relative risks and benefits of dUCB with MRD, MUD, and MMUD as sources of allogeneic HSCs for transplantation. In this study, we found that myeloablative conditioning followed by dUCBT is associated with similar rates of LFS compared with adult donor types. While delayed engraftment and the resulting higher risk of early NRM remain barriers to the successful use of dUCBT, marked reduction in relapse risk and lower risks of acute and chronic GVHD are advantages.

Registry and single center-based studies have previously shown that outcomes after UCBT using single unit grafts containing an adequate number of cells are comparable with that observed after the transplantation of marrow or peripheral blood from HLA-MRD or -MUD.4,8,16,17,25,26 Despite the reduction in HLA matching requirements, the low cell dose in a UCB graft has markedly restricted the use of UCB as the majority of adults cannot find a single UCB unit that provides the recommended nucleated cell dose of 2.5 x 10^7/kg.11 To overcome the cell dose barrier, we first established the safety of dUCB transplantation.14 This study extends observations in earlier smaller studies and provides the first
In addition to demonstrating a similar LFS, one of the most compelling evidence that dUCB units broadens the application of UCB to larger recipients and results in a LFS comparable with that observed using the gold standard of HLA-MRD and MUD.

In addition to demonstrating a similar LFS, one of the most intriguing findings of this study is the marked reduction in risk of relapse after dUCBT. While we and others have shown a reduced risk of relapse after dUCBT relative to that observed with single UCB grafts, to our knowledge there has been no other large analysis comparing dUCB and other HSC sources. As the number of dUCBT increases, registry studies may allow further analysis to better understand the low risk of relapse/enhanced graft-versus-leukemia. One possible explanation is simply the greater use of more mismatched grafts in the setting of dUCBT. Eapen et al and Rocha et al have previously shown lower risks of relapse in recipients of 2-antigen mismatched single UCB units relative to HLA matched marrow in children and 5-6/6 HLA matched UCBT, respectively. Whether each unit contributes to the graft-versus-leukemia effect independently is unknown. It is also possible that killer-cell immunoglobulin-like receptor-ligand mismatching after UCBT may be associated with reduced relapse risk. However, this remains controversial. While our data do not support an effect on the incidence of relapse, Willemze et al have observed an association between killer-cell immunoglobulin-like receptor-ligand mismatch and lower risk of relapse. Alternatively, the lower risk of relapse may reflect in vivo selection of the cord with the greater inherent immune reactivity. In the majority of dUCBT, only one cord ultimately engrafts eliminating the other via immunologic reactivity. This in vivo selection may explain both the greater antitumor effect seen with dUCBT compared with the use of single units, as well as the increased incidence of grade 2 acute GVHD in recipients of dUCB transplantation compared single unit recipients. While this analysis suggests that dUCBT may be associated with a reduced risk of relapse, the findings of this retrospective analysis must still be interpreted with caution.

As with single UCBT, the use of dUCB grafts is associated with a higher risk of NRM. The majority of nonrelapse deaths in dUCBT recipients occurred within the first 100 days with most deaths attributed to graft failure, infection, and hemorrhage. As in other reports, hematopoietic recovery was delayed after dUCBT compared with adult donor types. Given the adverse influence of slow hematopoietic recovery on NRM, novel strategies that shorten the time to neutrophil recovery after dUCBT, such as Notch-mediated ex vivo expansion or mesenchymal stem cell–based ex vivo expansion, may reduce NRM and further improve outcomes. In addition, lower risks of grade 2-4 acute and chronic GVHD after dUCBT compared with MUD and MMD transplantation might be expected to reduce the risk of opportunistic infection and impaired quality of life.

Ideally, a randomized study would be planned to verify these observations. However, there are logistical issues that will make this difficult. Although dUCBT is available to most, other stem cell sources are restricted by HLA matching requirements in addition to inherent delays associated with donor testing and clearance. Until then, we are limited to multi center or registry reports. While registry based studies will likely have the advantage of larger numbers of patients, there is always the risk of heterogeneity in eligibility criteria, treatment plans and supportive care between...
transplant centers. Added uncertainties including the impact of peripheral blood (PB) or bone marrow (BM) as a graft source may also influence the interpretation of future analyses. Available registry-based data showed higher risk of GVHD for PB recipients, but similar survival for both BM and PB. Importantly, future studies comparing rates of immune recovery, risks of opportunistic infection, and other late effects, including quality of life, in recipients of the various HSC sources are needed.

In conclusion, we recommend that patients with hematologic malignancy who lack an available HLA MRD or MUD be considered for UCBT. In circumstances where an adequate single UCB unit is not available (defined in this study as a cell dose > 3.0 \times 10^7 \text{nucleated cells/kg}), a dUCBT is a reasonable alternative. The remarkably low relapse risk after dUCBT is intriguing and requires further research to elucidate the underlying mechanism of this potential benefit.

Acknowledgments

We thank Pablo Rubinstein, MD, Director of the Placental Blood Program at the New York Blood Center, for having us consider the possibility of double umbilical cord blood transplantation and compelling us to move it forward as a new treatment that could potentially address the limitation of cell dose. We also thank Michael J. Franklin, MS (UM) for assistance in editing.

References


This work was supported by grants from the National Cancer Institute CA65493 (C.G.B. and J.E.W.) and CA18029 (F.R.A.), the Children’s Cancer Research Fund (J.E.W., T.E.D., and M.R.V.), American Cancer Society Scholar Award RSG-08-181-01-LLB (M.R.V.), and The Damon Runyon Cancer Research Foundation Clinical Investigator Award CI-35-07 (C.D.).

Authorship

Contribution: C.G.B. was involved in conception, design of analysis and interpretation of the data, drafting of the article, and final approval of the version to be published; J.A.G., D.J.W., A.E.W., T.A.G., M.R.V., and F.R.A. were involved in interpretation of data, critical revision for important intellectual content, and final approval of the version to be published; T.E.D. was involved in conception, design and statistical analysis, and final approval of the version to be published; and J.E.W. and C.D. were involved in conception, design analysis and interpretation of data, critical revision for important intellectual content, and final approval of the version to be published.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Claudio G. Brunstein, Department of Medicine, Mayo Mail Code 480, 420 Delaware St SE, Minneapolis, MN 55455; e-mail: bruns072@umn.edu.


Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Claudio G. Brunstein, Jonathan A. Gutman, Daniel J. Weisdorf, Ann E. Woolfrey, Todd E. DeFor, Theodore A. Gooley, Michael R. Verneris, Frederick R. Appelbaum, John E. Wagner and Colleen Delaney